IDEA award from J&J
We are delighted to be selected for funding from Johnson & Johnson Innovation’s IDEA award. This program aims to accelerate the development of new approaches to improving the detection and diagnosis of AL amyloidosis.
Funds from the program will support our research on early diagnosis of amyloidosis. We aim to find out whether antibody light chains that can aggregate as amyloid fibrils are unstable enough that we can identify them in blood samples. This could lead to a test for AL amyloidosis that would identify people at risk, who could benefit from early treatment.
J&J make the only drug approved specifically for AL amyloidosis, the monoclonal antibody daratumumab, so this support for our research should be considered a potential conflict of interest, although the company has no direct influence on the work that we will carry out. We are very grateful for the support.